2.25
0.45%
+0.010
CASI Pharmaceuticals Inc stock is currently priced at $2.25, with a 24-hour trading volume of 10,084.
It has seen a +0.45% increased in the last 24 hours and a -26.95% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.25 pivot point. If it approaches the $2.35 resistance level, significant changes may occur.
CASI Pharmaceuticals Inc Stock (CASI) Financials Data
CASI Pharmaceuticals Inc (CASI) Revenue 2024
CASI reported a revenue (TTM) of $33.88 million for the quarter ending December 31, 2023, a -21.41% decline year-over-year.
CASI Pharmaceuticals Inc (CASI) Net Income 2024
CASI net income (TTM) was -$26.94 million for the quarter ending December 31, 2023, a +34.32% increase year-over-year.
CASI Pharmaceuticals Inc (CASI) Cash Flow 2024
CASI recorded a free cash flow (TTM) of -$26.70 million for the quarter ending December 31, 2022, a +36.94% increase year-over-year.
CASI Pharmaceuticals Inc (CASI) Earnings per Share 2024
CASI earnings per share (TTM) was -$2.03 for the quarter ending December 31, 2023, a +32.33% growth year-over-year.
CASI Pharmaceuticals Inc Stock (CASI) Latest News
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Cap:
|
Volume (24h):